Centrus Energy (LEU): what it does, how it makes money, and why SMRs need its fuel

The standard $LEU story lumps Centrus in with the uranium miners: a nuclear name that goes up when uranium does. That misses what makes it unusual. Centrus does not dig uranium. It enriches it, and it runs the only US-licensed facility that has produced the specific enriched fuel most next-generation reactors are designed to use.

The more accurate frame: if small modular reactors and advanced reactors get built at scale, they need a fuel called HALEU, and today Centrus is the only US producer. That is a genuine chokepoint. It is also an early one: production is still at first-of-kind scale, and the commercial-scale plant is a build-out that runs into the 2030s. This piece walks through what Centrus does, how it makes money, where it sits in the nuclear stack, and the scale-up risk underneath. Market figures are as of 2026-10-02 unless noted; company figures are from Centrus's SEC filings, dated where used.

Why it matters now

The stock closed at $139.27 on 2026-10-02, down about 18% over a month and about 60% over a year over a stretch in which Centrus signed its $900M DOE HALEU contract and three new HALEU supply contracts. A chokepoint story and a falling price can coexist when the market is pricing timing and dilution: the chokepoint only pays at scale if the plant gets built and the reactors that need the fuel get built on schedule, and the build is now being funded partly with new shares. That is the question worth answering carefully.

What does Centrus do?

Centrus is a nuclear fuel company. Its core activity is enrichment: raising the share of the fissile isotope U-235 in uranium so it can be used as reactor fuel.

Today's large reactors burn low-enriched uranium, at up to 5% U-235. Most advanced reactor and small modular reactor designs, including those from Oklo, NuScale, X-energy and TerraPower, are built around HALEU, enriched to between 5% and 20%. HALEU lets those reactors run smaller, longer and more efficiently. The desk's framing is blunt: no HALEU, no SMRs at commercial scale.

Per QA's desk thesis, the structure is what makes Centrus matter:

• The 2024 US ban on Russian uranium imports removed what had been the dominant source of HALEU.
• Centrus's Piketon, Ohio facility is the only US-licensed plant that has produced HALEU: a single demonstration cascade run under a DOE contract signed in 2022, with the first HALEU delivered in 2023.
• The Department of Energy is now paying for the scale-up. On 2026-07-01 Centrus signed a firm fixed-price $900M contract (announced as a task order on 2026-01-05) to add commercial-scale HALEU enrichment at Piketon, paid in milestones, with a first delivery of one metric ton of HALEU due by July 2032 and two DOE options for 5 tonnes each at $17M per tonne (10-Q, filed 2026-08-06).

What changed on the existing cascade: its DOE production phase ended in mid-June 2026. The DOE converted the next option into three months of maintenance and storage with no HALEU production (through 2026-09-30, for $15M), has said it does not currently intend to exercise further options, and its proposed FY2027 budget does not fund cascade operations. Centrus says it is working with the DOE on agreements to run the cascade privately on a commercial basis, with no assurance they are reached (10-Q, 2026-08-06). As of this update, no 8-K has reported such an agreement.

How Centrus makes money

Most of the revenue today is not HALEU. It is the LEU segment: selling enrichment (separative work units, SWU) and uranium to utilities that run today's reactor fleet, much of it from contracts with fixed commitments. The Technical Solutions segment holds the government work, including the HALEU cascade contract.

Q2 2026 (quarter ended 2026-06-30, reported 2026-08-05):

• Revenue $176.1M, up 14% year on year; LEU segment $153.4M, Technical Solutions $22.7M.
• GAAP net income $16.8M, down from $28.9M, mainly on higher stock compensation and advanced-technology spending.
• Backlog $4.5B, extending to 2040: about $3.7B in the LEU segment, of which about $3.0B is contingent LEU and HALEU sales tied to the Piketon expansion ($2.4B under definitive agreements), plus about $0.8B in Technical Solutions, which is largely the HALEU cascade contract the DOE does not plan to extend.
• 2026 guidance: revenue $450M to $500M, capital deployment $350M to $500M, first new centrifuge completed at Oak Ridge, Tennessee by year-end.

The HALEU business is the growth story, and it is still early: shipments so far are first-of-kind quantities for the DOE, and the new commercial contracts start delivering around 2030. Every step up requires new centrifuge cascades, which are capital-intensive. That is the number to hold onto through the rest of this piece.

The funding: cash, a raise and warrants

Centrus held $1.87B of cash and equivalents at 2026-06-30 (10-Q). On 2026-09-09 it priced an underwritten offering through Guggenheim and Barclays (8-K, 2026-09-11; prospectus supplement 2026-09-09):

• 500,000 new shares plus pre-funded warrants for 2,005,513 shares, at $199.64 per share, about $500M gross and about $489M net.
• Attached common warrants for up to 6,992,382 more shares in four series, exercisable at $226.86, $272.24, $317.61 and $362.98. If all were exercised for cash, the company estimates about $2B of additional proceeds.

Two things follow. The quoted market cap (computed on about 19.7M Class A shares) understates the economic share count once the pre-funded warrants are counted. And the warrant strikes sit well above the 2026-10-02 close, so they bring in cash only if the stock recovers into those ranges.

The same 8-K disclosed advanced talks to buy an existing domestic manufacturing supplier for about $115M to $125M (about $160M of 2025 revenue), with no definitive agreement signed at the time.

Where it sits in the nuclear bubble

Centrus sits in QA's Nuclear / SMR bubble and maps onto the Nuclear theme.

The useful way to place Centrus is by position in the fuel chain. Miners dig uranium. Enrichers like Centrus turn it into reactor fuel. Reactor developers like Oklo ($OKLO) and NuScale ($SMR) build the machines that burn it, and operators of today's fleet, like Vistra with its existing nuclear plants, sell the power. Centrus's value rises and falls with the reactor developers downstream, because they are the future buyers of HALEU.

Those buyers are now signing. Since August Centrus has filed three HALEU supply contracts: X-energy (LEU and HALEU for advanced reactors, deliveries from 2030, 8-K 2026-08-06), Radiant Industries (8-K 2026-09-09) and Antares Nuclear (8-K 2026-09-17), the last two with deliveries scheduled to begin before the end of the decade. Contract values were not disclosed in the filings.

Its peers show the same linkage. LEU's tightest correlations in the QA universe (252 trading days, market beta stripped out, as of 2026-10-03) run to Oklo (0.78), NuScale (0.75) and Nano Nuclear Energy ($NNE, 0.73), all reactor-developer names, ahead of uranium producers like Denison Mines ($DNN, 0.67) and Uranium Energy ($UEC, 0.66). LEU trades with the SMR story, not with the uranium price. The full peer table is on /stocks/leu.

The numbers

The Street mean target is an estimate, an average of analyst opinions, not a promise or a QA view. On a name whose payoff depends on reactors that are not built yet, it mostly measures how much of that future the consensus is willing to count.

The bull case

• A real chokepoint: the only US-licensed facility that has produced HALEU, the fuel most advanced reactors and SMRs are designed for.
• The Russian import ban removed the previous dominant supplier.
• A signed $900M firm fixed-price DOE contract funds part of the commercial-scale HALEU build.
• Offtake is turning into paper: X-energy, Radiant and Antares contracts, and a $4.5B backlog with $2.4B of the contingent part under definitive agreements.
• A large cash position, topped up by about $489M net in September 2026.

The bear case

• Early scale. HALEU shipments so far are first-of-kind DOE quantities; the new commercial contracts deliver from around 2030.
• The existing cascade has lost its government funding path: no production in the July to September 2026 option, no further DOE options intended, no FY2027 budget line. A private commercial deal is not yet signed.
• Capital intensity and dilution. Guidance calls for $350M to $500M of capital deployment in 2026 alone, and the September raise added pre-funded warrants and up to about 7M more shares through common warrants.
• Single-site risk. Piketon is the only US site that has produced HALEU, so any disruption there hits the whole story.
• The multiple re-rated on the SMR thesis, with reversion risk if commercial SMR deployment slips.

How to access

Centrus Energy trades on the NYSE as LEU. To trade it from a US-retail account alongside the rest of the nuclear names, see /stack/ibkr. The live ETF holdings breakdown (VanEck $NLR at 5.1%, Global X $URA at 2.9%, as of 2026-10-02) is on /stocks/leu.

The full teardown video is on /stocks/leu. Subscribing to the digest on that page sends the Centrus Teardown Dossier free; the paid version is at /shop/leu-dossier and is included in /pro, along with bubble-correlation shifts and rule-based alerts on LEU.

What to watch

• Whether Centrus and the DOE sign an agreement to run the existing HALEU cascade privately now that the maintenance-only option period ended on 2026-09-30.
• Milestones under the $900M DOE contract, and the first new centrifuge at Oak Ridge, guided for completion by year-end 2026. Q3 2026 results are expected in early November; the date was not yet announced at this update.
• Whether the supplier acquisition disclosed on 2026-09-11 reaches a definitive agreement, and any exercise of the September warrants.
• SMR deployment timelines at Oklo, NuScale, X-energy and the others, since they set when contracted HALEU demand turns into deliveries.
• The curated $183 level (marked 2026-04-25) sits about 31% above the 2026-10-02 close, so it is an overhead reference, not support. It is an observable level, not a trade level or a target.

---

Live data on this ticker: /stocks/leu. Price, ETF holdings, bubble correlation, curated levels, bot positions.

Bubble context: /bubbles/nuclear-smr. The cluster this name belongs to and how it's moving.

QuantAbundance is educational research. Nothing here is investment advice. See /disclosures.